Phil Roche

CEO / CSO

Phil Roche picture

Phil Roche

Jenthera Therapeutics Inc.

CEO / CSO

Phil Roche Eng.D: Dr Roche is the CEO/CSO of Jenthera Therapeutics and the inventor of Jenthera’s proprietary non-viral, non-lipid gene editing therapeutic platform. Over the past 4 years he has built this gene editing platform, evaluated potential therapeutic applications that led to several in-vivo proofs of concept validations that have pre-clinical relevance in solid tumor and B-cell malignancies. He holds a PhD from the University of Manchester, UK/Astrazeneca in analytical science, and holds graduate degrees in molecular biology & biochemistry. Over his postdoctoral period he focused upon the integration of molecular biology, photonics, nanotechnology and biosensing developments leading to a series of inventions & patents covering nanomaterials, nanotherapeutics & ultrafast nucleic acid diagnostic systems. Since 2018 he has been advancing and developing engineered CRISPR systems to advance targeted CRISPR RNP delivery to cells and address challenges in CRISPR function such as enhanced HDR, production & immunogenicity.